meayamycin

inhibits pre-mRNA splicing; has antineoplastic activity; structure in first source

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Neoplasms (Cancer) 08/01/2009 - "Here, we report the picomolar antiproliferative activity of meayamycin against various cancer cell lines and multidrug-resistant cells. " 11/09/2023 - "Meayamycin D induced alternative splicing of MCL-1, showed strong synergism with venetoclax in drug-resistant lung cancer cells, and was cancer-specific over normal cells. "
2.	Lung Neoplasms (Lung Cancer) 08/01/2009 - "Meayamycin exhibited specificity toward human lung cancer cells compared with nontumorigenic human lung fibroblasts and retained picomolar growth-inhibitory activity against multidrug-resistant cells. " 11/09/2023 - "Meayamycin D induced alternative splicing of MCL-1, showed strong synergism with venetoclax in drug-resistant lung cancer cells, and was cancer-specific over normal cells. "
3.	Breast Neoplasms (Breast Cancer) 08/01/2009 - "Its analogue, meayamycin, is two orders of magnitude more potent as an antiproliferative agent against human breast cancer MCF-7 cells. " 03/07/2007 - "The inhibitions of human breast cancer MCF-7 cell proliferation by synthetic FR901464 and meayamycin were studied, and the GI50 values for these compounds were determined to be 1.1 nM and 10 pM, respectively. "